Business Wire
13 Jun 2026, 15:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
INCY's candidate INCA033989 achieved rapid, robust, and sustained clinical and molecular responses in patients with Myelofibrosis (MF) and Essential Thrombocythemia (ET). — Positive clinical trial data for a drug candidate in high-unmet-need indications typically drives significant upward price movement for the biotech developer.
+0.80INCA033989 was reported to be well tolerated in patients with MF and ET. — A strong safety profile reduces the risk of regulatory rejection and increases the likelihood of commercial viability.
+0.40Which stocks this story touches
The company reported positive clinical data showing rapid and robust responses for its drug candidate.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
